心脏肿块的诊断与分期:18F-FDG-PET联合CMR对比增强CT联合CMR的额外价值
回顾性纳入28例心脏肿块患者,评估18F-FDG-PET联合心脏磁共振(CMR)对肿块定性和分期的价值。CMR定性敏感度86.7%、特异度100%;PET敏感度93.3%、特异度84.6%;两者联合兼顾PET高敏感度(92.9%)与CMR高特异度(100%)。分期方面PET优于增强CT。
要点
- CMR定性恶性心脏肿块敏感度86.7%、特异度100%、准确率92.9%。
- 18F-FDG-PET定性敏感度93.3%、特异度84.6%、准确率89.3%。
- PET联合CMR定性兼顾PET敏感度92.9%与CMR特异度100%。
核心结论
- 18F-FDG-PET联合CMR较任一单独模态提高了心脏肿块的定性能力。
- 18F-FDG-PET的分期诊断性能优于增强CT。
- 本研究提示CMR联合18F-FDG-PET对心脏肿块的定性和分期最有效。
研究设计与样本
- 回顾性识别同时接受CMR、增强CT和18F-FDG-PET的心脏肿块患者。
- 共纳入28例患者,中位年龄60.5岁,女性占60.7%。
- 以组织学为恶性金标准、对抗凝治疗的反应为血栓金标准。
主要发现
- CMR定性敏感度86.7%、特异度100%、阳性预测值100%、阴性预测值86.7%、准确率92.9%。
- 18F-FDG-PET定性敏感度93.3%、特异度84.6%、阳性预测值87.5%、阴性预测值91.7%、准确率89.3%。
- CMR联合18F-FDG-PET定性敏感度92.9%、特异度100%。
- 分期患者层面正确诊断:18F-FDG-PET 66.7% vs 增强CT 55.6%。
- 分期器官层面18F-FDG-PET 10个 vs 增强CT 7个;病灶层面18F-FDG-PET >29个 vs 增强CT >25个。
临床怎么用
- 本研究提示CMR联合18F-FDG-PET对心脏肿块的定性和分期最有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Characterization of malignant cardiac masses is usually performed with cardiac magnetic resonance (CMR) and staging with whole-body contrast-enhanced computed tomography (CECT). In this study, our objective was to evaluate the role of 18Fluor-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) with CMR for both characterization and staging of cardiac masses. METHODS: Patients with cardiac masses who underwent CMR, CECT, and 18F-FDG-PET were retrospectively identified. For the characterization of cardiac masses, we calculated the respective performances of CMR alone, 18F-FDG-PET alone, and the combination of 18F-FDG-PET and CMR. For staging, we compared head-to-head the respective performances of 18F-FDG-PET and CECT. Histology served as gold standard for malignancy, and response to anticoagulation for thrombus. RESULTS: In a total of 28 patients (median age 60.5 years, 60.7% women), CMR accurately distinguished malignant from benign masses with sensitivity (Se) of 86.7%, specificity (Sp) of 100%, positive predictive value (PPV) of 100%, negative predictive value (NPV) of 86.7%, and accuracy of 92.9%. 18F-FDG-PET demonstrated 93.3% Se, 84.6% Sp, 87.5% PPV, 91.7% NPV, and 89.3% accuracy. Combining CMR with 18F-FDG-PET allowed to benefit from the high sensitivity of 18F-FDG-PET (92.9%) and the excellent specificity of CMR (100%) for malignant diseases. For staging, 18F-FDG-PET outperformed CECT on per-patient (66.7% vs 55.6% correct diagnosis, respectively), per-organ (10 vs 7 organs, respectively), and per-lesion basis (> 29 vs > 25 lesions, respectively). CONCLUSION: Combining 18F-FDG-PET with CMR improved the characterization of cardiac masses compared to each modality alone. Additionally, the diagnostic performance of 18F-FDG-PET was better than CECT for staging. This study suggests that the combination of CMR and 18F-FDG-PET is the most effective for the characterization of cardiac masses and the staging of these lesions.
引用
- Mikail N, Males L, Hyafil F, et al. Diagnosis and staging of cardiac masses: additional value of CMR with 18F-FDG-PET compared to CMR with CECT. Eur J Nucl Med Mol Imaging. 2022. PMID: 35247063. doi:10.1007/s00259-022-05709-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。